단일 광자 방사 단층촬영(SPECT) : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the single photon emission computed tomography market size was valued at USD 2.30 billion in 2025 and is estimated to grow from USD 2.37 billion in 2026 to reach USD 2.78 billion by 2031, at a CAGR of 3.24% during the forecast period (2026-2031).

This report is Segmented by System Type (Standalone SPECT and Hybrid SPECT/CT), Detector Technology (NaI(Tl) Anger Cameras and Solid-State Digital CZT SPECT), Application (Cardiology, and More), End-User (Hospitals & Health Systems, and More), Radioisotope (Tc-99m, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Single Photon Emission Computed Tomography (SPECT) Market Trends and Insights

Growing Burden of Oncology and Cardiovascular Diseases

Global cancer incidence hit 20 million new cases in 2022 and is projected to surge 77% by 2050 as populations age. Parallel to this trend, cardiovascular disease caused 19.2 million deaths in 2023, keeping nuclear cardiology in high demand. SPECT remains the first-line gatekeeper: bone scans stage metastatic disease and myocardial-perfusion imaging triages revascularization candidates. The American Heart Association's 2024 guideline reaffirmed SPECT for assessing myocardial viability, solidifying procedure volumes. Hospitals increasingly install hybrid SPECT/CT units to capture oncologic attenuation correction and coronary calcium scoring in a single visit, reinforcing system-replacement momentum.

Accelerating Adoption of Hybrid SPECT/CT Systems

Hybrid configurations accounted for 62.46% revenue in 2025 and will outpace standalone gamma cameras with a 5.45% CAGR to 2031. January 2025 joint guidelines from SNMMI, ASNC, and SCCT defined hybrid SPECT/CT as standard cardiac practice, mandating attenuation correction to curb false positives. GE HealthCare's Aurora, cleared by the FDA in May 2025, uses a 75 cm bore and 40 mm crystal to trim scan time 30%, while Siemens' Symbia Pro.specta ROI calculator shows payback in under three years for high-volume sites. Hospitals view hybrid adoption as future-proof, enabling theranostics dosimetry and quantitative SPECT imaging that standalone cameras cannot handle. Capital budgets pivot accordingly despite higher acquisition costs.

Vulnerability of Mo-99/Tc-99m Global Supply Chain

Six reactors generate 95% of the world's Mo-99, making outages disruptive. When Curium's European reactors paused in October 2024, United Kingdom clinics rationed doses, extending cardiac waitlists by weeks. Hospitals reverted to higher-dose thallium-201 protocols, highlighting a critical safety and efficiency setback. Reactor operators must also transition from highly enriched uranium targets to low-enriched fuel, temporarily lowering yields by about 20%, compounding supply tension. NorthStar's RadioGenix provides a cyclotron-based alternative, yet current output covers only a fraction of demand. Until redundancy improves, the Single-Photon Emission Computed Tomography market remains exposed to isotope shocks.

Other drivers and restraints analyzed in the detailed report include:

1. Advancements in Digital CZT and AI-Enabled Reconstruction
2. Strengthening Tc-99m Generator and Radiopharmacy Networks
3. Capital Intensity and Budget Constraints for SPECT/CT Upgrades

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Hybrid SPECT/CT platforms captured 62.46% of 2025 revenue and are predicted to grow at a 5.45% CAGR through 2031. This dominance stems from integrated attenuation correction, anatomical registration, and theranostics capabilities that justify a 40% premium over standalone units. GE HealthCare's Aurora, FDA-cleared in May 2025, trims acquisition time 30%, lifting daily myocardial-perfusion throughput to 20 patients. Siemens' Symbia Pro.specta supports isotopes up to 588 keV, enabling Lu-177 post-therapy scans. Standalone gamma cameras survive in mobile fleets and rural settings where CT adds limited benefit. Digirad's portable Ergo unit, priced under USD 250,000, fills this niche but lacks hybrid features essential for ACR oncology accreditation.

Hospitals view hybrid systems as strategic assets that future-proof nuclear-medicine departments. ROI calculators demonstrate breakeven in under three years when repeat studies drop 18% and same-day reporting accelerates billing cycles. Single-Photon Emission Computed Tomography market size for hybrid platforms is forecast to reach USD 1.9 billion by 2031, accounting for nearly 70% of total equipment revenue. As accreditation bodies tighten standards, the share gap between hybrid and standalone units will widen, reinforcing the former's leadership within the Single-Photon Emission Computed Tomography market.

Sodium-iodide (NaI) cameras held 63.56% of 2025 revenue, yet CZT systems are advancing at the fastest clip. Full-ring CZT scanners provide 4-to-10-fold sensitivity and 5% energy resolution, enabling 1 mSv cardiac studies that rival PET dose levels. Spectrum Dynamics' Veriton-CT, a 360° CZT ring, halves scan times with organ-specific geometries but carries a USD 1 million-plus list price. Kaiser Permanente adopted CZT-based cardiac amyloidosis screening in April 2025, validating clinical differentiation in a large integrated network.

Cost and supply advantages keep NaI relevant, particularly in emerging markets. Still, Single-Photon Emission Computed Tomography market share migration favors CZT, projected to rise above 45% by 2031. AI denoising workflows amplify performance gains, making CZT the detector of choice for outpatient centers chasing productivity. Vendors hedge by dual-detector portfolios, but future R&D resources tilt toward semiconductor-based designs.

Complete Report Scope:

• By System Type
  • Standalone SPECT Systems
  • Hybrid SPECT/CT Systems
• By Detector Technology
  • NaI(Tl) Anger Cameras
  • Solid-state Digital CZT SPECT
• By Application
  • Cardiology
  • Oncology
  • Neurology
  • Endocrine/Thyroid
  • Other Applications
• By End-user
  • Hospitals & Health Systems
  • Diagnostic Imaging Centers
  • Specialty & Academic Centers
• By Radioisotope
  • Tc-99m
  • Ra-223
  • Ga-67
  • I-123
  • Other Radioisotopes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 42.23% of 2025 revenue, buoyed by 15-20 million annual myocardial-perfusion studies and policy incentives supporting domestic Mo-99 supply. DOE's USD 32 million grant to SHINE Technologies and CMS's proposed USD 10 Mo-99 add-on de-risk isotope logistics, stabilizing procedure volumes. High installed bases temper growth, so the region advances at a moderate 3.5% CAGR through 2031 as hospitals stretch upgrade cycles to ten years. Nonetheless, hybrid SPECT/CT installations concentrate in bariatric-capable and theranostics-ready platforms such as GE's Aurora.

Asia-Pacific will post the fastest 4.54% CAGR, propelled by China's 1,200-plus PET/CT fleet that spurs downstream demand for lower-cost SPECT in tier-two cities and India's mandated detector-linearity upgrades. United Imaging's aggressively priced hybrid systems win provincial tenders, while Japanese centers maintain per-capita utilization near U.S. levels. Regulatory fragmentation slows cross-border equipment flows, yet International Atomic Energy Agency technical-cooperation projects in Southeast Asia expand nuclear-medicine access, seeding long-term growth.

Europe advances at 3.18% CAGR. Germany and France refresh fleets on seven-year cycles, but reactor maintenance at Belgium's BR2 and the Netherlands' Pallas periodically restricts isotope supply, causing utilization dips. Middle East-Africa and South America together deliver mid-single-digit growth as Gulf Cooperation Council hospital expansions and Brazil's public procurement cycles lift installed bases. Site-of-service migration and private imaging centers gain traction in Gulf states offering bundled cardiac check-up packages.

1. Bracco
2. Canon
3. Cardinal Health (Radiopharmacies)
4. Curium Pharma (Generators & Kits)
5. Digirad
6. GE Healthcare
7. Jubilant Radiopharma
8. Kromek (CZT supply)
9. Lantheus SPECT (Generators & Agents)
10. Mediso Medical Imaging Systems
11. Neusoft Medical Systems
12. NorthStar Medical Radioisotopes
13. NTP Radioisotopes
14. Koninklijke Philips
15. Redlen Technologies (CZT supply)
16. Siemens Healthineers
17. Spectrum Dynamics Medical
18. United Imaging Healthcare

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Burden of Oncology and Cardiovascular Diseases
  • 4.2.2 Accelerating Adoption of Hybrid SPECT/CT Systems
  • 4.2.3 Advancements in Digital CZT and AI-Enabled Reconstruction
  • 4.2.4 Strengthening Tc-99m Generator and Radiopharmacy Networks
  • 4.2.5 Replacement and Upgrade Cycles of Legacy Gamma Cameras
  • 4.2.6 Expansion of Theranostics and Quantitative SPECT Workflows
• 4.3 Market Restraints
  • 4.3.1 Vulnerability of Mo-99/Tc-99m Global Supply Chain
  • 4.3.2 Capital Intensity and Budget Constraints for SPECT/CT Upgrades
  • 4.3.3 Competitive Substitution from PET/CT in Oncology
  • 4.3.4 Limited Availability and Cost of Detector-Grade CZT
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By System Type
  • 5.1.1 Standalone SPECT Systems
  • 5.1.2 Hybrid SPECT/CT Systems
• 5.2 By Detector Technology
  • 5.2.1 NaI(Tl) Anger Cameras
  • 5.2.2 Solid-state Digital CZT SPECT
• 5.3 By Application
  • 5.3.1 Cardiology
  • 5.3.2 Oncology
  • 5.3.3 Neurology
  • 5.3.4 Endocrine/Thyroid
  • 5.3.5 Other Applications
• 5.4 By End-user
  • 5.4.1 Hospitals & Health Systems
  • 5.4.2 Diagnostic Imaging Centers
  • 5.4.3 Specialty & Academic Centers
• 5.5 By Radioisotope
  • 5.5.1 Tc-99m
  • 5.5.2 Ra-223
  • 5.5.3 Ga-67
  • 5.5.4 I-123
  • 5.5.5 Other Radioisotopes
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East & Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East & Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Bracco Imaging
  • 6.3.2 Canon Medical Systems
  • 6.3.3 Cardinal Health (Radiopharmacies)
  • 6.3.4 Curium Pharma (Generators & Kits)
  • 6.3.5 Digirad Corporation
  • 6.3.6 GE HealthCare
  • 6.3.7 Jubilant Radiopharma
  • 6.3.8 Kromek (CZT supply)
  • 6.3.9 Lantheus SPECT (Generators & Agents)
  • 6.3.10 Mediso Medical Imaging Systems
  • 6.3.11 Neusoft Medical Systems
  • 6.3.12 NorthStar Medical Radioisotopes
  • 6.3.13 NTP Radioisotopes SOC Ltd
  • 6.3.14 Koninklijke Philips NV
  • 6.3.15 Redlen Technologies (CZT supply)
  • 6.3.16 Siemens Healthineers
  • 6.3.17 Spectrum Dynamics Medical
  • 6.3.18 United Imaging Healthcare

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment